89035-91-6

Basic information

• Product Name: N-[4-(Trifluoromethyl)benzoyl]glycine
• Synonyms: N-[4-(Trifluoromethyl)benzoyl]glycine
• CAS NO: 89035-91-6
• Molecular Formula: C₁₀H₈F₃NO₃
• Molecular Weight: 247.1706296
• Product Categories: Amines;Aromatics;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 89035-91-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[4-(Trifluoromethyl)benzoyl]glycine(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(Trifluoromethyl)benzoyl]glycine(89035-91-6)
• EPA Substance Registry System: N-[4-(Trifluoromethyl)benzoyl]glycine(89035-91-6)

Safety Data

• Hazardous Substances Data: 89035-91-6(Hazardous Substances Data)

Upstream product

• 868842-48-2 (4-Trifluoromethylbenzoylamino)acetic acid tert-butyl ester 
• 329-15-7 4-trifluoromethyl-phenyl acetyl chloride 
• 56-40-6 glycine 

Downstream Products

• 868842-49-3 4-(4-benzyloxy benzylidene)-2-(4-trifluoromethylphenyl)-4H-oxazol-5-one 
• 1373150-45-8 ethyl 2-(4-(trifluoromethyl)phenyl)-1H-imidazole-5-carboxylate 
• 205925-54-8 (Z)-2-[4-(trifluoromethyl)benzoylamino]-N-butyl-3-(4-chlorophenyl)-2-propenamide 
• 425380-46-7 (Z)-2-(p-trifluoromethylbenzoylamino)-N-(3'-dimethylaminopropyl)-3-(1-naphthyl)-2-propenamide 
• 800393-90-2 (Z)-N-methyl-3-(1-naphthyl)-2-(4-trifluoromethylbenzoylamino)-2-propenamide 
• 425380-64-9 (Z)-2-(p-trifluoromethylphenyl)-4-(1-naphthylmethylene)-5(4H)-oxazolone 
• 1334392-36-7 C₁₃H₁₄F₃N₃O₂ 

Relevant articles and documents

Design, Synthesis, and Evaluation of the Anticancer Properties of a Novel Series of Imidazolone Fused Pyrazolo[1,5-a]pyrimidine Derivatives

A novel series of imidazolone fused pyrazolo[1,5-a]pyrimidine derivatives has been designed and synthesized using a convergent approach, and the structures of these compounds were confirmed by 1H NMR, 13C NMR, ESI-MS, and IR analyses. These new compounds were tested for their in vitro antiproliferative activity using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Out of the 20 derivatives prepared in the current study, compounds 8h, 8n, and 8r exhibited good anticancer activities tested against HeLa cells and HepG2 cells. However, the in vitro anticancer activity of compound 8r against HeLa, HepG2, and MCF-7 cell lines is superior to the marketed drugs Paclitaxel and SAHA.

Synthesis of di- and tri-substituted imidazole-4-carboxylates via PBu3-mediated [3+2] cycloaddition

Some new di- and trisubstituted imidazole-4-carboxylates were prepared from amidoacetic acids 3 in the present report. The key step to establish such imidazole- 4-carboxylates stemmed from the PBu3-mediated [3+2] cycloaddition between in situ-generated Δ2-oxazolinone 4 and ethyl cyanoformate6. Our results indicated that trisubstituted imidazoles 7-20 were afforded in better yields than those of disubstituted imidazoles 21-27. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications1 to view the free supplemental file. Copyright Taylor & Francis Group, LLC.

Anthranilate 4H-oxazol-5-ones: Novel small molecule antibacterial acyl carrier protein synthase (AcpS) inhibitors

D-optimal design and Projection to Latent Structures (PLS) analysis were used to optimize screening hit 5 (B. subtilis AcpS IC50: 15 μM, B. subtilis MIC: >200 μM) into a series of 4H-oxazol-5-one, small molecule, antibacterial, AcpS inhibitors. Specifically, 15, 16 and 18 show μM or sub-μM AcpS inhibition (IC50s: 15: 1.1 μM, 16: 1.5 μM, 18: 0.27 μM) and moderate antibacterial activity (MICs: 12.5-50 μM) against B. subtilis, E. faecalis ATCC, E. faecalis VRE and S. pneumo+.